CCEL 8-K
Cryo Cell International Inc (CCEL)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
The Board of Directors of the Company has fixed October 27, 2026 as the date for the 2026 Annual Meeting of Stockholders of the Company (the “Annual Meeting”), and has fixed September 21, 2026 as the record date for determining stockholders entitled to notice of and to vote at the Annual Meeting.
Pursuant to Article II, Section 3 of the Company’s Bylaws, the deadline for stockholders to provide timely notice of business proposed to be brought before the Annual Meeting was July 27, 2026. Pursuant to Article II, Section 10 of the Company’s Bylaws, the deadline for stockholders to provide timely notice of director nominations for consideration at the Annual Meeting was also July 27, 2026.
A copy of the Company’s Bylaws, as amended, is included as Exhibit 3.1 to the Current Report on Form 8-K filed with the United States Securities and Exchange Commission on December 11, 2018.
.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Cryo-Cell International, Inc. |
|
|
|
|
Date: |
September 14, 2026 |
By: |
/s/ David Portnoy |
|
|
|
David Portnoy, Chairman and Co-CEO |